BioInvent announces achievement of a research milestone event in its collaboration with Exelixis triggering a USD 1 million milestone payment

September 7, 2023 2:20 AM

LUND, SE / ACCESSWIRE / September 07, 2023 / BioInvent International (STO:BINV)Collaboration focuses on novel antibodies for use in immuno-oncology therapeuticsTarget and antibody discovery performed using BioInvent's proprietary n-CoDeR® antibody library and F.I.R.S.T™ screening platformLund, Sweden - September 7, 2023 - BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and...

Read more

Petros Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

September 6, 2023 4:05 PM

NEW YORK, NY / ACCESSWIRE / September 6, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a pioneer in expanding consumer access to medication through over the counter (OTC) pathways, announces today that Fady Boctor, President and Chief Commercial Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference. The conference is being held on September 11 - 13, 2023 at the Lotte New York Palace...

Read more

Patient Population for the Clinical Trials of ITV-1 has been Established by the European Medicines Agency ("EMA")

September 6, 2023 8:45 AM

Start date is expected by the end of 2023 / beginning of 2024. VIRO also offers an update on Diabetic trials and Sagaliam transaction.ALLEN, TX / ACCESSWIRE / September 6, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).Virogentics, Inc. ("VIRO"), a wholly owned subsidiary of Enzolytics, Inc. (the "Company" or "ENZC"), a drug development biotech company, announced today that based on the Bulgarian population of HIV-infected...

Read more

Imagene Announces LungOI, the First AI-Based NSCLC Molecular Panel for Immediate Cancer Biomarker Profiling

September 6, 2023 8:00 AM

Rapid NSCLC Biomarker Test already demonstrated its significant impact and clinical benefits as part of a lung cancer clinical study.TEL AVIV, ISRAEL / ACCESSWIRE / September 6, 2023 / Imagene, an emerging leader in the field of AI-based precision oncology, is pleased to announce the release of LungOI™, the world's first AI-based Non-Small Cell Lung Cancer (NSCLC) molecular panel, identifying actionable alterations from the biopsy image...

Read more

Ensysce Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

September 5, 2023 8:15 AM

SAN DIEGO, CA / ACCESSWIRE / September 5, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that its management has been invited to present at the H.C. Wainwright 25th Annual Global Investment Conference (the "conference") taking place in New York, NY on September 11-13, 2023.The Company's Chief Executive...

Read more

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference

September 5, 2023 8:05 AM

FRAMINGHAM, MA / ACCESSWIRE / September 5, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY and...

Read more

Biogenysis, Inc. Announces Partnering with Khalpey AI Lab and Contenta, Ltd. to Incorporate AI in Microbiome Analysis to Identify Biomarkers for Use in Accurately Predicting Alzheimer's Disease Onset and Prevention.

September 5, 2023 8:00 AM

COLLEGE STATION, TX / ACCESSWIRE / September 5, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).Biogenysis, Inc. ("BGEN"), a wholly owned subsidiary of Enzolytics, Inc. (the "Company" or "ENZC"), a drug development biotech company, announced today a continued partnership with Khalpey AI Lab (https://khalpey-ai.com ) and Contenta, Ltd., Estonia, to identify biomarkers for early onset Alzheimer's disease. Such a discovery could...

Read more

Biophytis to Participate at the H.C. Wainwright 25th Global Investment Conference in New York

September 4, 2023 5:30 PM

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 4, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in...

Read more

IPF Has A 0% Survival Rate Without Lung Transplant And A Median Survival Time Of 2-5 Years From Diagnosis - Could GRI-0621 Be The Solution?

September 1, 2023 9:15 AM

LA JOLLA, CA / ACCESSWIRE / September 1, 2023 / Idiopathic Pulmonary Fibrosis (IPF) is a serious chronic lung disease characterized by the thickening and stiffening of the lung tissue surrounding the air sacs. The exact cause of IPF is unknown, but it is believed to involve a combination of genetic and environmental factors. Scarring and fibrosis of lung tissue lead to the loss of the lungs' ability to effectively transfer oxygen to the...

Read more

Dermata to Present at the H.C. Wainwright 25th Annual Global Investment Conference

August 31, 2023 9:00 AM

SAN DIEGO, CA / ACCESSWIRE / August 31, 2023 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced it will be featured as a presenting company at the H.C. Wainwright 25th Annual Global Investment Conference, being held September 11-13, 2023. The in-person venue for the event is the Lotte New York...

Read more

New Clinical Data and Cutting-Edge Advances to Be Presented at the 2023 Oligonucleotide Therapeutics Society Meeting

August 30, 2023 11:00 AM

SAN DIEGO, CA / ACCESSWIRE / August 30, 2023 / This year's Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) will be held in Barcelona, Spain, from October 22-25. At the annual meeting, leaders and students from around the world present and discuss their discoveries over four days, and attendees engage in a cross-disciplinary exchange, fostering the development of ground-breaking new ideas. OTS is an open, nonprofit forum to...

Read more

Lexaria Provides Update on Investigational New Drug Application Progress

August 30, 2023 9:20 AM

KELOWNA, BC / ACCESSWIRE / August 30, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is providing this update on the status of the Company's anticipated submission of an Investigational New Drug ("IND") application with the U.S. Food and Drug Administration ("FDA") for its planned U.S. Phase 1b Hypertension Clinical Trial designated as HYPER-H23-1.As...

Read more

BioInvent International AB: Interim report January-June 2023

August 30, 2023 2:20 AM

LUND, SWEDEN / ACCESSWIRE / August 30, 2023 / BioInvent International (STO:BINV) "In the quarter, we had impressive early signals of efficacy in the Phase 1/2 trial of our lead drug candidate, the novel anti-FcgRIIB antibody BI-1206, in combination with rituximab in non-Hodgkin's lymphoma (NHL). A fourth complete response was observed in the 100 mg dose expansion cohort in the intravenous arm of the study." - Martin Welschof, CEO of...

Read more

AppYea Secures US Patent for Innovative Sleep Apnea Detection Using Speech Analysis

August 28, 2023 9:35 AM

New Patent Promises Affordable and Convenient Sleep Apnea Diagnostics; Market Projected to Reach US$ 9.27 Billion by 2033GAN YAVNE, ISRAEL / ACCESSWIRE / August 28, 2023 / SleepX, a subsidiary of AppYea Inc. (OTC:APYP), focusing on the development of accurate wearable monitoring solutions to treat sleep apnea and snoring, announces it has been granted a patent (US 11,672,472 B2) by the United States Patent and Trademark Office, titled: "Methods...

Read more

HanchorBio and Henlius Announce Strategic Collaboration to Develop Innovative Immunotherapies

August 28, 2023 7:30 AM

SHANGHAI, CHINA and TAIPEI, TAIWAN / ACCESSWIRE / August 28, 2023 / HanchorBio Inc., a global clinical-stage biotechnology company focusing on the discovery and development of innovative immuno-biomedicines, and Shanghai Henlius Biotech, Inc., a global biopharmaceutical company developing biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases, today announced that the two companies have entered into a strategic...

Read more

Ischemix, Inc. Completes Successful Phase 1 Trial of Novel Compound to Treat Traumatic Brain Injury (TBI); Preparing for Conduct of Phase 2 Trial

August 25, 2023 4:00 PM

- CMX-2043, a novel, proprietary cytoprotective drug candidate, demonstrated excellent safety and tolerability in a Phase 1 single ascending and multiple ascending dose (SAD-MAD) clinical trial. - CMX-2043 has previously demonstrated safety and efficacy in extensive preclinical pharmacology, toxicology and TBI translational studies. - CMX-2043 will be Phase 2-ready by the first quarter of 2024.GRAFTON, MA / ACCESSWIRE / August 25, 2023 /...

Read more

Biogenysis’ International Patent Application, Covering Its Anti-SARS-CoV-2 Monoclonal Antibodies, Advances to Prosecution in Europe and as a U.S. National Stage Application.

August 24, 2023 8:00 AM

COLLEGE STATION, TX / ACCESSWIRE / August 24, 2023 / Biogenysis, Inc. (OTC PINK:ENZC) (or the "Company"). Biogenysis, a subsidiary of Enzolytics, Inc., announces the progress of its Patent Cooperation Treaty (PCT) application covering its inventions relating to Anti-SARS-CoV-2 Monoclonal Antibodies. The PCT application has now advanced to filing as a U.S. National Stage Application in the U.S. Patent Office and as a formal European Patent...

Read more

assisTek Announces Updated CORE Platform Release for Fall 2023

August 24, 2023 8:00 AM

PA-based clinical technology provider assisTek has announced new features to its upcoming software release, including AI Integration, a Proprietary OS, SSO & Remote Provisioning, to add to its growing suite of eCOA & ePRO solutions.DOYLESTOWN, PA / ACCESSWIRE / August 24, 2023 / Pennsylvania-based Clinical Technology company assisTek is thrilled to announce their next-generation, advanced software platform designed to further streamline...

Read more

Bionoid Pharma Extends Letter of Intent to Acquire Global Alerts Corp.

August 24, 2023 7:00 AM

"Paving the Way for a Safer World Through Advanced Emergency Communications"TORONTO, ON / ACCESSWIRE / August 24, 2023 / Bionoid Pharma, Inc. ("BINP" or the "Company") (OTC PINK:BINP) is pleased to announce the extension of the effective period of a Letter of Intent (LOI), along with its exclusivity provisions, with Global Alerts Corp., as initially disclosed on March 22, 2023. The Company confirmed that the LOI, originally set to expire on...

Read more

Biovica Announces the Start of a DiviTum(R) TKa Clinical Trial

August 24, 2023 4:50 AM

UPPSALA, SWEDEN / ACCESSWIRE / August 24, 2023 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) Biovica, active in cancer diagnostics, today announces the initiation of a prospective clinical trial to study the correlation between DiviTum TKa levels and the effects of medication dose reductions in the care of metastatic breast cancer patients."We are very proud to be partnering with Yale on such an important prospective...

Read more